Navigation Links
Cephalon Recommends Shareholders Reject Valeant Nominees
Date:4/7/2011

FRAZER, Pa., April 7, 2011 /PRNewswire/ -- Cephalon, Inc. (NASDAQ: CEPH) said today in a preliminary consent revocation statement filed with the Securities and Exchange Commission (SEC) that its Board of Directors has recommended that shareholders reject Valeant Pharmaceuticals International, Inc.'s proposals to remove and replace Cephalon's current Board of Directors and not deliver any consent solicitation cards to Valeant.  On April 5, 2011, the Board rejected Valeant's unsolicited proposal to purchase the Company for $73 per share, concluding that the non-binding proposal is inadequate and not in the best interests of Cephalon's shareholders.  

In urging Cephalon's shareholders to reject Valeant's proposals and to not deliver any consent solicitation cards to Valeant, Cephalon noted that:  

  • Cephalon's Current Board of Directors is Best Positioned to Maximize Value for Cephalon's Shareholders.  Cephalon's Board of Directors, which is predominantly composed of independent and disinterested directors, has a strong track record of acting in shareholders' best interests.  The current Board of Directors is intimately familiar with Cephalon's business, its day-to-day operations and its products and pipeline, and is in the best position to continue to review, develop and adapt the Company's plan to maximize value for all of the Company's stockholders.  Valeant's proposed nominees do not have this same knowledge of, and experience with, Cephalon.
  • Valeant Has No Duty to Act in Cephalon Shareholders' Best Interests.  The Board noted that Valeant has no duty to act in the best interests of Cephalon's shareholders (including when selecting nominees to serve as Cephalon directors) and that it would be in Valeant's and its shareholders' interest to buy Cephalon at the lowest possible pric
    '/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cephalon First Quarter 2011 Earnings Conference Call Tuesday, May 3, 2011 at 5:00 p.m. EDT
2. Cephalon Announces Positive Topline Results From a Phase IV Study of NUVIGIL in Shift Work Disorder
3. Cephalon to Hold Public Memorial Service to Celebrate the Life of Company Founder, Frank Baldino, Jr., Ph.D.
4. Cephalon Mourns the Passing of Founder, Chairman and CEO, Frank Baldino Jr., Ph.D.
5. Cephalon Announces Chairman and CEO to Remain on Medical Leave of Absence Indefinitely
6. Cephalon Reports Record Earnings and Raises 2010 Guidance
7. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
8. Cephalon Announces Chairman and CEO to Take Medical Leave of Absence
9. Cephalon Completes Acquisition of Arana Therapeutics
10. Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
11. Cephalon Quarterly Conference Call Invitation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Mass. , Feb. 27, 2015 ... of the NCATS rare-diseases portfolio " in ... a new financing technique to reduce the risk ... diseases and potentially unlock new levels of funding ... The product of a unique collaboration between scientists ...
(Date:2/27/2015)... Md. (PRWEB) February 27, 2015 ... Chromatography system (Nexera UC) can sequentially analyze up ... separation combined with high-sensitivity detection of targets by ... is designed to fulfill the measurement requirements of ... in food products, drug delivery and search for ...
(Date:2/27/2015)... Brighton, Illinois (PRWEB) February 27, 2015 ... Matt Sims, General Manager of State Line Farms, received ... Award recognizes a producer, under the age of 35, ... , "It is an honor to win the Tomorrow's ... to discovering who won the Top Producer Award and ...
(Date:2/27/2015)... BOSTON , Feb. 27, 2015   PureTech ... identifying, inventing and commercializing disruptive products and technologies in ... Christopher Viehbacher , former CEO and Member of the ... Directors.  "It,s has been a pleasure ... very excited that we will be working together more ...
Breaking Biology Technology:New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4
... S.C., Aug. 6 Denham Capital,("Denham") announced ... $60 million in VitAG,Corporation ("VitAG"). VitAG technology ... product capable of competing with and,outperforming conventional ... multiple biosolids-to-fertilizer manufacturing plants., "Denham,s investment ...
... Million; GAAP EPS $0.53; Adjusted EPS $0.48, CORONA, ... ), a leading specialty pharmaceutical,company, today reported financial results ... Quarter 2008 Results, Net revenue for the second ... million, or $0.53 per diluted share. Net income for ...
... on Tuesday, August 12, 2008, ROCKVILLE, Md., ... a clinical-stage pharmaceutical company developing,therapeutics for the treatment ... for the three and six-month periods ending June,30, ... The Company reported a net loss for the ...
Cached Biology Technology:Denham Capital to Invest $60 Million in VitAG, Recycler of Municipal Biosolids 2Watson Pharmaceuticals Reports Second Quarter 2008 Results 2Watson Pharmaceuticals Reports Second Quarter 2008 Results 3Watson Pharmaceuticals Reports Second Quarter 2008 Results 4Watson Pharmaceuticals Reports Second Quarter 2008 Results 5Watson Pharmaceuticals Reports Second Quarter 2008 Results 6Watson Pharmaceuticals Reports Second Quarter 2008 Results 7Watson Pharmaceuticals Reports Second Quarter 2008 Results 8Watson Pharmaceuticals Reports Second Quarter 2008 Results 9Watson Pharmaceuticals Reports Second Quarter 2008 Results 10Watson Pharmaceuticals Reports Second Quarter 2008 Results 11Watson Pharmaceuticals Reports Second Quarter 2008 Results 12Watson Pharmaceuticals Reports Second Quarter 2008 Results 13Watson Pharmaceuticals Reports Second Quarter 2008 Results 14Watson Pharmaceuticals Reports Second Quarter 2008 Results 15Watson Pharmaceuticals Reports Second Quarter 2008 Results 16Watson Pharmaceuticals Reports Second Quarter 2008 Results 17EntreMed Reports Second Quarter 2008 Financial Results 2EntreMed Reports Second Quarter 2008 Financial Results 3EntreMed Reports Second Quarter 2008 Financial Results 4EntreMed Reports Second Quarter 2008 Financial Results 5
(Date:1/22/2015)... 2015  Today, FreeWavz ( www.FreeWavz.com ), the developer ... on Fundable, https://www.fundable.com/freewavz . FreeWavz will be ... to meet customer demand. Logo - ... Invented by Dr. ...
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric ... recent success of the Wocket™ smart wallet at CES 2015 in ... named as one of the "11 Hot Products at CES" in a ... CES So Far" by Newseveryday.com and "The top 10 gadgets from CES ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... that it has been named an American Society ... Center of Excellence. The ASMBS Center of ... track record of favorable outcomes in bariatric surgery. ... of our experienced surgeons and our institutional commitment ...
... lakes and even wet soil, diatoms are unicellular algae ... these tiny phytoplankton could be harboring the next big ... walls by laying down submicron-sized lines of silica, a ... industrysilicon. If we can genetically control that process, we ...
... study by the University of Exeter has highlighted ... for conservation projects. Published online in the journal ... rates of captive carnivores that are released into ... three captive-born carnivores survives in the wild, with ...
Cached Biology News:Pennsylvania Hospital recognized for excellence in bariatric surgery 2In diatom, scientists find genes that may level engineering hurdle 2Captive carnivores not up to wild living 2
... multi-purpose, high gel-strength agarose suitable for a ... conventional constant field to Pulsed Field Gel ... strength and exclusion limits, Multi ABgarose can ... running times. This in turn means reduced ...
... molecular screening, low melting point agarose where ... is recommended for separation of nucleic acids ... PCR products. Micro ABgarose is also suited ... for blotting techniques. At a 3% concentration, ...
Sheep polyclonal to Salmonella Shoreditch ( Abpromise for all tested applications). Antigen: Native Salmonella shoreditch (Group D2)....
anti-achaete...
Biology Products: